NCT05007418View on ClinicalTrials.gov

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

STI-1492

Anti-CD38 A2 KOKI DAR T cells

Trial Locations (3)

73104

RECRUITING

University of Oklahoma, Oklahoma City

92868

NOT_YET_RECRUITING

UC Irvine, Orange

95817

NOT_YET_RECRUITING

UC Davis, Sacramento

All Listed Sponsors
lead

Sorrento Therapeutics, Inc.

INDUSTRY